This press section is intended for journalists and investors for a professional use.

WHAT’S NEW
AT VOLUNTIS ?

ABOUT VOLUNTIS

Voluntis is dedicated to developing companion software that empowers patients to self-manage their chronic disease in collaboration with their medical team.

DOWNLOAD PRESS KIT

Working on a Voluntis story? We can help.

Press contact :
Amélie Janson
(617) 245-4125

  • Meet Insulia®

    What is companion software?

  • Tomorrowland: medical treatment in 2020

Meet Insulia®

What is companion software?

Tomorrowland: medical treatment in 2020

PRESS RELEASES

December 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

November 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

October 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

Voluntis reports Business Review and Financial Results for first half of 2019

September 2019

Voluntis - Notice of Business review and results for the first half of 2019 Results to be announced on Thursday 19 September 2019 at 8:00am CEST

September 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

August 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

July 2019

Voluntis Announces Market Authorization for Oleena™, First Digital Therapeutic in Oncology

July 2019

Bilan semestriel du contrat de liquidité contracté avec ODDO Corporate Finance

July 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

July 2019

Voluntis maintains a strong and promising view for the company’s future

June 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

May 2019

Voluntis : Mise à disposition des documents préparatoires à l’Assemblée Générale mixte du 24 mai 2019

May 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

April 2019

Voluntis : Mise à disposition du Document de Référence 2018

April 2019

Voluntis appoints Berkley Nelson as Chief Growth Officer

March 2019

Voluntis – Annual results 2018

March 2019

Voluntis announces end of Roche Pharma France collaboration for ZEMY solution

March 2019

Voluntis receives CE Mark to add NPH/isophane insulin to Insulia

March 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

February 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

January 2019

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

December 2018

AbbVie and Voluntis to develop companion digital therapeutics

December 2018

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

November 2018

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

October 2018

Voluntis and AstraZeneca win prestigious Prix Galien MedStartUp Award for ‘Best Patient Engagement Technologies’ for eCO

October 2018

Jan Berger, MD, and Roberta Herman, MD, join Voluntis’ Board of Directors

October 2018

Voluntis announces end of multi-cancer extension for solution developed with Roche Pharma France

October 2018

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

September 2018

First-half 2018: expanded and strengthened abilities to pursue future growth

August 2018

Voluntis extends partnership with AstraZeneca in digital therapeutics for oncology

August 2018

Voluntis releases upgraded version of Insulia to improve user experience, including Spanish

August 2018

Information relative au nombre total de droits de vote et d’actions composant le capital social

July 2018

Voluntis announces the launch of Theraxium Oncology, an innovative digital platform for symptom management

July 2018

Results of the eCO trial published in the Journal of Clinical Oncology Informatics

July 2018

Information relative au nombre total de droits de vote et d’actions composant le capital social

May 2018

Voluntis successfully completes its IPO and raises €30.1m on the regulated market of Euronext in Paris

May 2018

Voluntis signs contract with US payer WellDyneRx for coverage of a digital therapeutic

April 2018

Voluntis announces the registration of its document de base, launching its initial public offering process on Euronext’s regulated market in Paris

March 2018

Voluntis and Roche Pharma France reinvent cancer patient support with digital therapeutics

January 2018

Voluntis and WellDoc Announce Partnership to Combine Diabetes Digital Therapeutic Offerings

December 2017

Voluntis launches Insulia Savings Program, making Insulia available at $0 copay

November 2017

Voluntis to integrate Insulia® with Onduo virtual diabetes clinic

November 2017

Insulia receives FDA clearance and CE mark to integrate Basaglar and Tresiba

October 2017

Digital Therapeutics Alliance Established to Advance Novel Technologies Aimed at Transforming Patient Clinical Outcomes

July 2017

Insulia® receives FDA clearance and CE mark to integrate Toujeo®

June 2017

Voluntis and Ascensia Diabetes Care announce technology partnership to help optimize insulin management for people with Type 2 diabetes

April 2017

Voluntis adds Scott Honken to Leadership Team to strengthen payer & provider focus

March 2017

Voluntis and Sanofi announce a global alliance to deliver digital insulin titration solutions for people with type 2 diabetes

February 2017

Voluntis and Livongo Partner to Deliver Insulin Titration App

December 2016

Voluntis receives FDA clearance and CE mark for Insulia® a first for digital applications supporting type 2 diabetes patients treated with basal insulin

December 2015

Voluntis and AstraZeneca to test companion mobile app in ovarian cancer studies with the US National Cancer Institute

September 2015

Roche Pharma France and Voluntis partner to develop first therapeutic companion solution for women afflicted with breast cancer

June 2015

Voluntis announces election of Eric Elliott as Chairman of the Board of Directors

VOLUNTIS IN THE NEWS

December 2018 - Insulin Nation

Basal Insulin Management is not easy. These new tools could help.

March 2018 - FierceBiotech

Roche, Voluntis expand digital therapeutics pact into solid tumors

January 2018 - Pharmacy Practice News

Adherence Goes Hi-Tech

February 2018 - McKinsey & Company

Digital Therapeutics: Preparing for Takeoff

February 2018 - The Economist

A Revolution in Health Care is Coming

November 2017 - Pharmacy Times

Insulin Dosing Apps Are on Their Way

November 2017 - Mobihealthnews

Voluntis gets FDA clearance to add last two basal insulins to app

November 2017 - Pharmaphorum

7 questions: the Digital Therapeutic Alliance’s Pierre Leurent

November 2017 - Cancer Therapy Advisor

Mobile Apps: The Future of Cancer Care?

June 2017 - Endocrine Today

Ascensia, Voluntis to Combine Technologies

March 2017 - Close Concerns

Sanofi and Voluntis Announce Expanded Partnership

January 2017 - A Sweet Life

Insulia, Software by Prescription for Type 2 Diabetes Management

October 2016 - Les Echos

Voluntis : un leader mondial de l'e-santé

July 2016 - iMedicalApps

eCO Study App created by pharma to specifically monitor two key side effects

June 2016 - The doctor weighs in

Creating Medical Apps That Actually Get Used

BRAND ASSETS